Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death.

Kidney Int Rep · 2022 · PMC9039467 · PMID 35497810

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

19 Interestingly, there was a trend for increased DGF in the patients treated with alemtuzumab (although this did not reach statistical significance).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.